

# Elliott M Antman

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/2782070/elliott-m-antman-publications-by-year.pdf>

**Version:** 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

149 papers	10,419 citations	38 h-index	102 g-index
165 ext. papers	12,293 ext. citations	11.3 avg, IF	5.96 L-index

#	Paper	IF	Citations
149	Association of Convalescent Plasma Treatment With Clinical Status in Patients Hospitalized With COVID-19: A Meta-analysis.. <i>JAMA Network Open</i> , <b>2022</b> , 5, e2147331	10.4	4
148	The inclusion of augmented intelligence in medicine: A framework for successful implementation.. <i>Cell Reports Medicine</i> , <b>2022</b> , 3, 100485	18	1
147	Development and Validation of a Treatment Benefit Index to Identify Hospitalized Patients With COVID-19 Who May Benefit From Convalescent Plasma.. <i>JAMA Network Open</i> , <b>2022</b> , 5, e2147375	10.4	6
146	Ideal Cardiovascular Health in Young Adults With Established Cardiovascular Diseases.. <i>Frontiers in Cardiovascular Medicine</i> , <b>2022</b> , 9, 814610	5.4	1
145	Sodium and Health: Old Myths and a Controversy Based on Denial.. <i>Current Nutrition Reports</i> , <b>2022</b> , 1	6	4
144	Exploring patient experiences coping with using multiple medications: a qualitative interview study. <i>BMJ Open</i> , <b>2021</b> , 11, e046860	3	0
143	Digital health device measured sleep duration and ideal cardiovascular health: an observational study. <i>BMC Cardiovascular Disorders</i> , <b>2021</b> , 21, 497	2.3	1
142	Serial assessment of biomarkers and the risk of stroke or systemic embolism and bleeding in patients with atrial fibrillation in the ENGAGE AF-TIMI 48 trial. <i>European Heart Journal</i> , <b>2021</b> , 42, 1698-1708	70.5	11
141	Randomized, Double-Blind Comparison of Half-Dose Versus Full-Dose Edoxaban in 14,014 Patients With Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , <b>2021</b> , 77, 1197-1207	15.1	10
140	Data from Digital Health Devices Informs Ideal Cardiovascular Health. <i>Journal of Personalized Medicine</i> , <b>2021</b> , 11,	3.6	4
139	Intracranial hemorrhage in patients with atrial fibrillation receiving anticoagulation with warfarin or edoxaban: An in-depth analysis from the ENGAGE AF-TIMI 48 randomized trial. <i>Journal of Clinical Neuroscience</i> , <b>2021</b> , 86, 294-300	2.2	3
138	Obesity and Ideal Cardiovascular Health: Results from the My Research Legacy Study. <i>Obesities</i> , <b>2021</b> , 1, 36-48		
137	Comparative Effectiveness of Aspirin Dosing in Cardiovascular Disease. <i>New England Journal of Medicine</i> , <b>2021</b> , 384, 1981-1990	59.2	37
136	Edoxaban versus warfarin in patients with atrial fibrillation in relation to the risk of stroke: A secondary analysis of the ENGAGE AF-TIMI 48 study. <i>American Heart Journal</i> , <b>2021</b> , 235, 132-139	4.9	0
135	A precision medicine approach to sex-based differences in ideal cardiovascular health. <i>Scientific Reports</i> , <b>2021</b> , 11, 14848	4.9	0
134	A Biomarker-Centric Approach to Drug Discovery and Development: Lessons Learned from the Coronavirus Disease 2019 Pandemic. <i>Journal of Pharmacology and Experimental Therapeutics</i> , <b>2021</b> , 376, 12-20	4.7	1
133	Patients with diabetes mellitus and atrial fibrillation treated with non-vitamin K antagonist oral anticoagulants: meta-analysis of eight outcomes in 58,634 patients across four randomized controlled trials. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , <b>2021</b> , 7, f40-f49	6.4	5

132	Edoxaban versus Warfarin in Patients with Atrial Fibrillation at the Extremes of Body Weight: An Analysis from the ENGAGE AF-TIMI 48 Trial. <i>Thrombosis and Haemostasis</i> , <b>2021</b> , 121, 140-149	7	8
131	An overview of the process, progress, and outcomes of a National Center for Accelerated Innovation: The Boston Biomedical Innovation Center Experience. <i>Journal of Clinical and Translational Science</i> , <b>2021</b> , 5, e137	0.4	
130	Comprehensive characterization of protein-protein interactions perturbed by disease mutations. <i>Nature Genetics</i> , <b>2021</b> , 53, 342-353	36.3	27
129	Sex, Permanent Drug Discontinuation, and Study Retention in Clinical Trials: Insights From the TIMI trials. <i>Circulation</i> , <b>2021</b> , 143, 685-695	16.7	3
128	Comparison of the Efficacy and Safety Outcomes of Edoxaban in 8040 Women Versus 13 065 Men With Atrial Fibrillation in the ENGAGE AF-TIMI 48 Trial. <i>Circulation</i> , <b>2021</b> , 143, 673-684	16.7	2
127	Nonculprit Lesion Myocardial Infarction Following Percutaneous Coronary Intervention in Patients With Acute Coronary Syndrome. <i>Journal of the American College of Cardiology</i> , <b>2020</b> , 75, 1095-1106	15.1	12
126	Efficacy and safety of edoxaban in patients with diabetes mellitus in the ENGAGE AF-TIMI 48 trial. <i>International Journal of Cardiology</i> , <b>2020</b> , 304, 185-191	3.2	13
125	Pooling Data From Individual Clinical Trials in the COVID-19 Era. <i>JAMA - Journal of the American Medical Association</i> , <b>2020</b> , 324, 543-545	27.4	45
124	Pharmacogenetic-guided and clinical warfarin dosing algorithm assessments with bleeding outcomes risk-stratified by genetic and covariate subgroups. <i>International Journal of Cardiology</i> , <b>2020</b> , 317, 159-166	3.2	0
123	Genetic profiling of fatty acid desaturase polymorphisms identifies patients who may benefit from high-dose omega-3 fatty acids in cardiac remodeling after acute myocardial infarction-Post-hoc analysis from the OMEGA-REMODEL randomized controlled trial. <i>PLoS ONE</i> , <b>2019</b> , 14, e0222061	3.7	4
122	Edoxaban Versus Warfarin Stratified by Average Blood Pressure in 19 679 Patients With Atrial Fibrillation and a History of Hypertension in the ENGAGE AF-TIMI 48 Trial. <i>Hypertension</i> , <b>2019</b> , 74, 597-605	8.5	6
121	Comparison of Events Across Bleeding Scales in the ENGAGE AF-TIMI 48 Trial. <i>Circulation</i> , <b>2019</b> , 140, 1792-1801	16.7	8
120	Left atrial structure and function and the risk of death or heart failure in atrial fibrillation. <i>European Journal of Heart Failure</i> , <b>2019</b> , 21, 1571-1579	12.3	21
119	Outcomes of Women Compared With Men After Non-ST-Segment Elevation Acute Coronary Syndromes. <i>Journal of the American College of Cardiology</i> , <b>2019</b> , 74, 3013-3022	15.1	30
118	Clinical outcomes, edoxaban concentration, and anti-factor Xa activity of Asian patients with atrial fibrillation compared with non-Asians in the ENGAGE AF-TIMI 48 trial. <i>European Heart Journal</i> , <b>2019</b> , 40, 1518-1527	9.5	34
117	Performance of the ABC Scores for Assessing the Risk of Stroke or Systemic Embolism and Bleeding in Patients With Atrial Fibrillation in ENGAGE AF-TIMI 48. <i>Circulation</i> , <b>2019</b> , 139, 760-771	16.7	54
116	Edoxaban and implantable cardiac device interventions: insights from the ENGAGE AF-TIMI 48 trial. <i>Europace</i> , <b>2019</b> , 21, 306-312	3.9	3
115	Relationship between body mass index and outcomes in patients with atrial fibrillation treated with edoxaban or warfarin in the ENGAGE AF-TIMI 48 trial. <i>European Heart Journal</i> , <b>2019</b> , 40, 1541-1550	9.5	53

114	Clinical events after interruption of anticoagulation in patients with atrial fibrillation: An analysis from the ENGAGE AF-TIMI 48 trial. <i>International Journal of Cardiology</i> , <b>2018</b> , 257, 102-107	3.2	14
113	Peri-operative Adverse Outcomes in Patients with Atrial Fibrillation Taking Warfarin or Edoxaban: Analysis of the ENGAGE AF-TIMI 48 Trial. <i>Thrombosis and Haemostasis</i> , <b>2018</b> , 118, 1001-1008	7	11
112	The Introduction and Clinical Use of Cardiac-Specific Troponin Assays. <i>Clinical Pharmacology and Therapeutics</i> , <b>2018</b> , 103, 31-33	6.1	6
111	Improving care at the population and individual level: lessons from SWEDHEART. <i>European Heart Journal</i> , <b>2018</b> , 39, 3777-3779	9.5	3
110	Edoxaban Versus Warfarin in Latin American Patients With Atrial Fibrillation: The ENGAGE AF-TIMI 48 Trial. <i>Journal of the American College of Cardiology</i> , <b>2018</b> , 72, 1466-1475	15.1	8
109	Modes and timing of death in 66 252 patients with non-ST-segment elevation acute coronary syndromes enrolled in 14 TIMI trials. <i>European Heart Journal</i> , <b>2018</b> , 39, 3810-3820	9.5	18
108	Linking Endogenous Factor Xa Activity, a Biologically Relevant Pharmacodynamic Marker, to Edoxaban Plasma Concentrations and Clinical Outcomes in the ENGAGE AF-TIMI 48 Trial. <i>Circulation</i> , <b>2018</b> , 138, 1963-1973	16.7	23
107	A novel risk prediction score in atrial fibrillation for a net clinical outcome from the ENGAGE AF-TIMI 48 randomized clinical trial. <i>European Heart Journal</i> , <b>2017</b> , 38, 888-896	9.5	29
106	Stroke and Mortality Risk in Patients With Various Patterns of Atrial Fibrillation: Results From the ENGAGE AF-TIMI 48 Trial (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48). <i>Circulation: Arrhythmia and Electrophysiology</i> , <b>2017</b> , 10,	6.4	94
105	Edoxaban for the Prevention of Thromboembolism in Patients With Atrial Fibrillation and Bioprosthetic Valves. <i>Circulation</i> , <b>2017</b> , 135, 1273-1275	16.7	94
104	Evaluating the Cardiovascular Safety of Nonsteroidal Anti-Inflammatory Drugs. <i>Circulation</i> , <b>2017</b> , 135, 2062-2072	16.7	18
103	Valvular Heart Disease Patients on Edoxaban or Warfarin in the ENGAGE AF-TIMI 48 Trial. <i>Journal of the American College of Cardiology</i> , <b>2017</b> , 69, 1372-1382	15.1	87
102	Impact of Spontaneous Extracranial Bleeding Events on Health State Utility in Patients with Atrial Fibrillation: Results from the ENGAGE AF-TIMI 48 Trial. <i>Journal of the American Heart Association</i> , <b>2017</b> , 6,	6	14
101	NIH Centers for Accelerated Innovations Program: principles, practices, successes and challenges. <i>Nature Reviews Drug Discovery</i> , <b>2017</b> , 16, 663-664	64.1	2
100	First experience with edoxaban and atrial fibrillation ablation - Insights from the ENGAGE AF-TIMI 48 trial. <i>International Journal of Cardiology</i> , <b>2017</b> , 244, 192-195	3.2	17
99	Digoxin Use and Subsequent Clinical Outcomes in Patients With Atrial Fibrillation With or Without Heart Failure in the ENGAGE AF-TIMI 48 Trial. <i>Journal of the American Heart Association</i> , <b>2017</b> , 6,	6	25
98	Concomitant Use of Single Antiplatelet Therapy With Edoxaban or Warfarin in Patients With Atrial Fibrillation: Analysis From the ENGAGE AF-TIMI48 Trial. <i>Journal of the American Heart Association</i> , <b>2016</b> , 5,	6	79
97	Impact of Renal Function on Outcomes With Edoxaban in the ENGAGE AF-TIMI 48 Trial. <i>Circulation</i> , <b>2016</b> , 134, 24-36	16.7	174

96	Precision medicine in cardiology. <i>Nature Reviews Cardiology</i> , <b>2016</b> , 13, 591-602	14.8	115
95	Mortality in Patients with Atrial Fibrillation Randomized to Edoxaban or Warfarin: Insights from the ENGAGE AF-TIMI 48 Trial. <i>American Journal of Medicine</i> , <b>2016</b> , 129, 850-857.e2	2.4	40
94	Edoxaban vs warfarin in patients with nonvalvular atrial fibrillation in the US Food and Drug Administration approval population: An analysis from the Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48 (ENGAGE AF-TIMI 48) trial. <i>American Heart Journal</i> , <b>2016</b> , 172, 144-51	4.9	13
93	Sudden Cardiac Death in Patients With Atrial Fibrillation: Insights From the ENGAGE AF-TIMI 48 Trial. <i>Journal of the American Heart Association</i> , <b>2016</b> , 5,	6	42
92	The Prognostic Significance of Cardiac Structure and Function in Atrial Fibrillation: The ENGAGE AF-TIMI 48 Echocardiographic Substudy. <i>Journal of the American Society of Echocardiography</i> , <b>2016</b> , 29, 537-44	5.8	22
91	Edoxaban Versus Warfarin in Atrial Fibrillation Patients at Risk of Falling: ENGAGE AF-TIMI 48 Analysis. <i>Journal of the American College of Cardiology</i> , <b>2016</b> , 68, 1169-1178	15.1	99
90	Cardiovascular Biomarker Score and Clinical Outcomes in Patients With Atrial Fibrillation: A Subanalysis of the ENGAGE AF-TIMI 48 Randomized Clinical Trial. <i>JAMA Cardiology</i> , <b>2016</b> , 1, 999-1006	16.2	45
89	Effect of Omega-3 Acid Ethyl Esters on Left Ventricular Remodeling After Acute Myocardial Infarction: The OMEGA-REMODEL Randomized Clinical Trial. <i>Circulation</i> , <b>2016</b> , 134, 378-91	16.7	112
88	Outcomes With Edoxaban Versus Warfarin in Patients With Previous Cerebrovascular Events: Findings From ENGAGE AF-TIMI 48 (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48). <i>Stroke</i> , <b>2016</b> , 47, 2075-82	6.7	57
87	Genetics and the clinical response to warfarin and edoxaban: findings from the randomised, double-blind ENGAGE AF-TIMI 48 trial. <i>Lancet, The</i> , <b>2015</b> , 385, 2280-7	40	126
86	Edoxaban effects on bleeding following punch biopsy and reversal by a 4-factor prothrombin complex concentrate. <i>Circulation</i> , <b>2015</b> , 131, 82-90	16.7	202
85	Edoxaban vs. warfarin in vitamin K antagonist experienced and naive patients with atrial fibrillation. <i>European Heart Journal</i> , <b>2015</b> , 36, 1470-7	9.5	42
84	Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial. <i>Lancet, The</i> , <b>2015</b> , 385, 2288-95	40	275
83	Fibrinolysis use among patients requiring interhospital transfer for ST-segment elevation myocardial infarction care: a report from the US National Cardiovascular Data Registry. <i>JAMA Internal Medicine</i> , <b>2015</b> , 175, 207-15	11.5	56
82	Cost-effectiveness of edoxaban vs warfarin in patients with atrial fibrillation based on results of the ENGAGE AF-TIMI 48 trial. <i>American Heart Journal</i> , <b>2015</b> , 170, 1140-50	4.9	22
81	Saving and Improving Lives in the Information Age: Presidential Address at the American Heart Association 2014 Scientific Sessions. <i>Circulation</i> , <b>2015</b> , 131, 2238-42	16.7	2
80	Diltiazem treatment for pre-clinical hypertrophic cardiomyopathy sarcomere mutation carriers: a pilot randomized trial to modify disease expression. <i>JACC: Heart Failure</i> , <b>2015</b> , 3, 180-8	7.9	105
79	Clinical practice guidelines for chronic cardiovascular disorders: a roadmap for the future. <i>JAMA - Journal of the American Medical Association</i> , <b>2014</b> , 311, 1195-6	27.4	7

78	Transition of patients from blinded study drug to open-label anticoagulation: the ENGAGE AF-TIMI 48 trial. <i>Journal of the American College of Cardiology</i> , <b>2014</b> , 64, 576-84	15.1	35
77	Clinical research and the development of medical therapeutics. <i>Circulation Journal</i> , <b>2014</b> , 78, 1267-71	2.9	3
76	Left atrial structure and function in atrial fibrillation: ENGAGE AF-TIMI 48. <i>European Heart Journal</i> , <b>2014</b> , 35, 1457-65	9.5	130
75	Reducing the risk of heart attack and stroke: the American Heart Association/American College of Cardiology prevention guidelines. <i>Circulation</i> , <b>2014</b> , 130, e48-50	16.7	
74	Cerebrovascular events in 21 105 patients with atrial fibrillation randomized to edoxaban versus warfarin: Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48. <i>Stroke</i> , <b>2014</b> , 45, 2372-8	6.7	43
73	Edoxaban versus warfarin in patients with atrial fibrillation. <i>New England Journal of Medicine</i> , <b>2013</b> , 369, 2093-104	59.2	3215
72	Concomitant administration of clopidogrel with statins or calcium-channel blockers: insights from the TRITON-TIMI 38 (trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38). <i>JACC: Cardiovascular Interventions</i> , <b>2013</b> , 6, 1275-81	5	31
71	Transforming clinical trials in cardiovascular disease: mission critical for health and economic well-being. <i>JAMA - Journal of the American Medical Association</i> , <b>2012</b> , 308, 1743-4	27.4	28
70	Systems pharmacology, pharmacogenetics, and clinical trial design in network medicine. <i>Wiley Interdisciplinary Reviews: Systems Biology and Medicine</i> , <b>2012</b> , 4, 367-83	6.6	34
69	Evidence and education. <i>Circulation</i> , <b>2011</b> , 123, 681-5	16.7	4
68	Response to Letter Regarding Article, Cost-Effectiveness of Prasugrel Versus Clopidogrel in Patients With Acute Coronary Syndromes and Planned Percutaneous Coronary Intervention: Results From the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis in Myocardial Infarction (TRITON-TIMI 38). <i>Circulation</i> , <b>2010</b> , 122, 1669-71	16.7	1
67	Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoagulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48). <i>American Heart Journal</i> , <b>2010</b> , 160, 435-44	4.9	377
66	Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. <i>Lancet, The</i> , <b>2009</b> , 374, 989-997	40	531
65	Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis In Myocardial Infarction) analysis. <i>Journal of the American College of Cardiology</i> , <b>2008</b> , 51, 2028-33	15.1	269
64	The specialty of emergency medicine: needed now more than ever before. <i>Annals of Emergency Medicine</i> , <b>2008</b> , 52, 317-9	2.1	1
63	Use of nonsteroidal antiinflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association. <i>Circulation</i> , <b>2007</b> , 115, 1634-42	16.7	589
62	Inside the FDA: The Business and Politics Behind the Drugs We Take and the Food We Eat. <i>Circulation</i> , <b>2005</b> , 112,	16.7	1
61	Cyclooxygenase inhibition and cardiovascular risk. <i>Circulation</i> , <b>2005</b> , 112, 759-70	16.7	207



60	Pharmacoinvasive therapy: the future of treatment for ST-elevation myocardial infarction. <i>Circulation</i> , <b>2004</b> , 109, 2480-6	16.7	42
59	Glycoprotein IIb/IIIa inhibitors in patients with unstable angina/non-ST-segment elevation myocardial infarction: appropriate interpretation of the guidelines. <i>American Heart Journal</i> , <b>2003</b> , 146, S18-22	4.9	23
58	Should evidence-based proof of efficacy as defined for a specific therapeutic agent be extrapolated to encompass a therapeutic class of agents?. <i>Circulation</i> , <b>2003</b> , 108, 2604-7	16.7	14
57	Enoxaparin as adjunctive antithrombin therapy for ST-elevation myocardial infarction: results of the ENTIRE-Thrombolysis in Myocardial Infarction (TIMI) 23 Trial. <i>Circulation</i> , <b>2002</b> , 105, 1642-9	16.7	190
56	Bivalirudin as a replacement for unfractionated heparin in unstable angina/non-ST-elevation myocardial infarction: observations from the TIMI 8 trial. The Thrombolysis in Myocardial Infarction. <i>American Heart Journal</i> , <b>2002</b> , 143, 229-34	4.9	52
55	Clinical trials in cardiovascular medicine. <i>Circulation</i> , <b>2001</b> , 103, E101-4	16.7	5
54	The search for replacements for unfractionated heparin. <i>Circulation</i> , <b>2001</b> , 103, 2310-4	16.7	62
53	Combination therapy with abciximab reduces angiographically evident thrombus in acute myocardial infarction: a TIMI 14 substudy. <i>Circulation</i> , <b>2001</b> , 103, 2550-4	16.7	366
52	Clinical Efficacy of Three Assays for Cardiac Troponin I for Risk Stratification in Acute Coronary Syndromes: A Thrombolysis In Myocardial Infarction (TIMI) 11B Substudy. <i>Clinical Chemistry</i> , <b>2000</b> , 46, 453-460	5.5	102
51	TIMI risk score for ST-elevation myocardial infarction: A convenient, bedside, clinical score for risk assessment at presentation: An intravenous nPA for treatment of infarcting myocardium early II trial substudy. <i>Circulation</i> , <b>2000</b> , 102, 2031-7	16.7	1067
50	The Long-term Pharmacologic Management of Atrial Fibrillation for Control of Rate and Rhythm. <i>Journal of Interventional Cardiac Electrophysiology</i> , <b>1999</b> , 3, 96-99		
49	Pathogenesis and pathology of coronary heart disease syndromes. <i>Journal of Thrombosis and Thrombolysis</i> , <b>1999</b> , 8, 167-89	5.1	12
48	The role of cardiac troponin-I (cTnI) in risk stratification of patients with unstable coronary artery disease. <i>Clinical Cardiology</i> , <b>1999</b> , 22, 13-6	3.3	18
47	Platelet Glycoprotein IIb/IIIa Inhibitors in Cardiovascular Disease. <i>Annals of Internal Medicine</i> , <b>1999</b> , 131, 235	8	
46	Pharmacological Therapy of Cardiac Arrhythmias. <i>Journal of Thrombosis and Thrombolysis</i> , <b>1998</b> , 6, 211-238	3.8	
45	The Thrombin Hypothesis: Dead or Alive?. <i>Journal of Thrombosis and Thrombolysis</i> , <b>1998</b> , 5, S137-S141	5.1	
44	Noninvasive Cardiac Imaging in Chest Pain Syndromes. <i>Journal of Thrombosis and Thrombolysis</i> , <b>1998</b> , 6, 239-252	5.1	
43	Reexamination of the Thrombin Hypothesis: What We Have Learned from TIMI 9B and GUSTO IIb. <i>Journal of Thrombosis and Thrombolysis</i> , <b>1997</b> , 4, 321-323	5.1	

42	Long-Term Pharmacologic Management of Atrial Fibrillation for Control of Rate and Rhythm. <i>Journal of Interventional Cardiac Electrophysiology</i> , <b>1997</b> , 1, 40-43		
41	The role of magnesium therapy in acute myocardial infarction. <i>Clinical Cardiology</i> , <b>1996</b> , 19, 841-4	3.3	8
40	Hirudin in acute myocardial infarction. Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9B trial. <i>Circulation</i> , <b>1996</b> , 94, 911-21	16.7	314
39	Atrial fibrillation and flutter: maintaining stability of sinus rhythm versus ventricular rate control. <i>Journal of Cardiovascular Electrophysiology</i> , <b>1995</b> , 6, 962-71	2.7	17
38	Magnesium in acute MI. Timing is critical. <i>Circulation</i> , <b>1995</b> , 92, 2367-72	16.7	41
37	A neural network system for detection of atrial fibrillation in ambulatory electrocardiograms. <i>Journal of Cardiovascular Electrophysiology</i> , <b>1994</b> , 5, 602-8	2.7	14
36	Current diagnosis and prescription for Marfan syndrome: when to operate. <i>Journal of Cardiac Surgery</i> , <b>1994</b> , 9, 174-6	1.3	8
35	Documented symptomatic bradycardia and symptom relief in patients receiving permanent pacemakers: an evaluation of the joint ACC/AHA pacing guidelines. <i>PACE - Pacing and Clinical Electrophysiology</i> , <b>1988</b> , 11, 1098-104	1.6	3
34	Pacemaker-mediated tachycardia initiated by coincident P-wave undersensing and ventricular blanking period. <i>PACE - Pacing and Clinical Electrophysiology</i> , <b>1985</b> , 8, 436-9	1.6	7
33	Nifedipine in the treatment of cardiovascular disease. <i>Pharmacotherapy</i> , <b>1981</b> , 1, 78-94	5.8	11
32	ST-Elevation Myocardial Infarction46-90		4
31	Antiplatelet Therapy in Peripheral Arterial Disease196-214		
30	Laboratory Assessment of Platelet Function and the Effects of Antiplatelet Agents15-29		
29	Programming CRT Devices180-219		1
28	Author Disclosure Table291-296		
27	Platelet Physiology and the Role of the Platelet in Ischemic Heart Disease1-14		
26	Antiplatelet Therapy in Acute Coronary Syndrome without ST Elevation143-163		
25	Antiplatelet Therapy in ST-Elevation Myocardial Infarction164-177		



- 24 Antiplatelet Therapy in Chronic Coronary Artery Disease178-195
- 23 Clinical use of Antiplatelet Agents in Cardiovascular Disease: Cerebrovascular Diseases215-229
- 22 Antiplatelet Therapy and Coronary Bypass Surgery: Risks and Benefits231-250
- 21 Management of Antiplatelet Therapy for Non-Cardiac Surgery251-264
- 20 Antiplatelet Therapy and Coronary Stents265-279
- 19 Cyclooxygenase Inhibitors31-46
- 18 Aspirin Response Variability and Resistance47-58
- 17 P2Y12 Inhibitors: Thienopyridines and Direct Oral Inhibitors59-76
- 16 Thienopyridine Response Variability and Resistance77-93
- 15 Pharmacology of Intravenous Glycoprotein IIb/IIIa Antagonists95-110
- 14 Intravenous P2Y12 Inhibitors111-124
- 13 Antiplatelet Effects of Thrombin Inhibitors and Fibrinolytic Agents125-142
- 12 Troubleshooting CRT Devices and Clinical Outcomes220-247
- 11 Implantation of a CRT Device156-179
- 10 Author Disclosure Table349-353
- 9 Non-CRT Pacing in the Failing Heart: Cardiac Contractility Modulation (CCM)284-296
- 8 Integrated Heart Failure Management in the Patient with Heart Failure Caused by Left Ventricular Systolic Dysfunction1-30
- 7 Pathobiology of Left Ventricular Dyssynchrony and Resynchronization31-56

6 Clinical Trials and Response to CRT130-155

2

5 Future Directions in Pacing to Support the Failing Heart319-335

4 Electrical Assessment of the Failing Heart57-91

3 Clinical Outcomes and Chronic Management of Device Patients297-318

2 Mechanical Assessment of the Failing Heart92-129

1 Non-CRT Pacing in the Failing Heart: Limiting Ventricular Pacing and Searching for Alternate Pacing Sites248-283